logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5476.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5476.produseast1
Our test collection | Collections | MSF Science Portal

test

Collection Content

See more collections

World Hepatitis Day 2022
World Hepatitis Day 2022
Each year hundreds of millions of people suffer from chronic or acute liver disease caused by hepatitis viruses, and over one million die. To mark World Hepatitis Day (July 28th) we bring you a selection of MSF research exploring how to better prevent, identify and treat hepatitis infection in lower-income countries and emergency contexts where the burden is heaviest. For example, in a South Sudanese camp for displaced people—a type of setting where poor sanitation and water quality regularly lead to hepatitis E outbreaks—MSF and the Ministry of Health (MoH) are conducting the world’s first reactive vaccination campaign against this disease, and evaluating the process and outcomes. In Cambodia, MSF and MoH collaborators found that a simplified community-based model of care for hepatitis C was safe and highly effective in diagnosing patients and in curing them with new antiviral drugs. It was also cost-effective, according to studies in several countries and patient populations. And these new drugs were safe and effective even in patients also being treated for drug-resistant tuberculosis.
Poster gallery (MSF Scientific Days International 2022)
Poster gallery (MSF Scientific Days International 2022)
No description available
World Hepatitis Day 2024
World Hepatitis Day 2024

Viral hepatitis is a significant cause of disease and death globally. Yet powerful new medical tools to combat hepatitis C and E still reach only a tiny fraction of people who desperately need them, especially in low-resource and emergency settings.


To mark World Hepatitis Day (July 28th) we highlight recent MSF research on making these breakthrough products more widely accessible and simpler to use.


For hepatitis C, where groundbreaking antiviral drugs can cure nearly all patients, MSF is developing comprehensive, community-based models of care that offer rapid screening, diagnosis, and treatment under one roof. In some settings programs focus on the specific needs of highly vulnerable populations, such as people living in remote areas, forcibly displaced refugees, or those co-infected with HIV or TB or who inject drugs.


Turning to prevention, MSF is exploring ways to use the Hepatitis E vaccine more effectively in areas where poor sanitation and water quality regularly lead to outbreaks. Studies in a South Sudanese camp for internally displaced people are strengthening evidence for the vaccine’s feasibility, efficacy, safety and community acceptance, especially for pregnant women and their fetuses. Another report analyzes strategies for overcoming barriers to widespread vaccine adoption.

View All Collections
Our test collection

Our test collection